Shots:
- Chiesi Group has entered into a definitive agreement to acquire KalVista Pharmaceuticals, expanding Chiesi’s rare immunology portfolio
- As per the deal, Chiesi will acquire KalVista for $27/share, representing the total deal value of ~$1.9B, with the transaction expected to close in Q3’26 & remaining shares acquired later via a second-step merger
- Upon completion, Chiesi will assume responsibility for Ekterly (sebetralstat), an oral on-demand hereditary angioedema therapy from KalVista, aiming to expand access & strengthen rare immunology capabilities through combined expertise
Ref: Businesswire | Image: KalVista | Press Release
Related News: KalVista Pharmaceuticals Reports EC and Swissmedic Approval of Ekterly (Sebetralstat) for Hereditary Angioedema (HAE)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
